Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial

W, Tang; Z, Cao; M, Han; Z, Wang; J, Chen; W, Sun; Y, Wu; W, Xiao; S, Liu; E, Chen; W, Chen; X, Wang; J, Yang; J, Lin; Q, Zhao; Y, Yan; Z, Xie; D, Li; Y, Yang; L, Liu; J, Qu; G, Ning; G, Shi; Q, Xie

doi:10.1101/2020.04.10.20060558

Public

Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial

Shared by NobleBlocks on Apr 14, 2020 • 12:00 AM UTC

Authors:

Tang W

Cao Z

Han M

Abstract

<h4>Objectives</h4> To assess the efficacy and safety of hydroxychloroquine (HCQ) plus standard–of–care (SOC) compared with SOC alone in adult patients with COVID–19. <h4>Design</h4> Multicenter, open–label, randomized controlled trial. <h4>Setting</h4> 16 government–designated COVID–19 treatment ce...

Discussions